Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001958829-23-000001
Filing Date
2023-08-03
Accepted
2023-08-03 07:49:35
Documents
1
Period of Report
2023-05-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 1905
  Complete submission text file 0001958829-23-000001.txt   3571
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Issuer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 4/F 16-17 LS-RO 91BEON-GIL DONGAN-GU ANYANG, GYEONGGI M5 14042
Business Address 4/F 16-17 LS-RO 91BEON-GIL DONGAN-GU ANYANG, GYEONGGI M5 14042 82 (31) 4558600
INCON Co., Ltd. (Reporting) CIK: 0001958829 (see all company filings)

State of Incorp.: M5 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-41184 | Film No.: 231138127